Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BBIO | US
0.15
0.60%
Healthcare
Biotechnology
30/06/2024
04/10/2024
25.23
25.81
26.05
25.12
BridgeBio Pharma Inc. engages in the discovery development and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265 a small molecule stabilizer of transthyretin or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy or ATTR-CM; BBP-831 a small molecule selective FGFR1-3 inhibitor which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631 an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia or CAH driven by 21-hydroxylase deficiency or 21OHD. The company also develops Encaleret a small molecule antagonist of the calcium sensing receptor or CaSR which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1 or ADH1; and BBP-711 for the treatment of hyperoxaluria as well as patients suffering from recurrent kidney stones. In addition it engages in developing products for Mendelian oncology and gene therapy diseases. BridgeBio Pharma Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research Inc. The company was founded in 2015 and is headquartered in Palo Alto California.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.3%1 month
47.7%3 months
51.0%6 months
52.2%-
-
123.68
-1.58
2.18
-9.40
27.25
-
-496.59M
4.74B
4.74B
-
-7.96K
-
32.10
-1.79K
8.42
16.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.17
Range1M
8.20
Range3M
8.66
Rel. volume
0.61
Price X volume
36.04M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -9.40 | 0.76 | Cheaper |
Ent. to Revenue | 27.25 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 123.68 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 51.02 | 74.67 | Lower Risk |
Debt to Equity | -1.58 | -1.82 | Cheaper |
Debt to Assets | 2.18 | 0.26 | Expensive |
Market Cap | 4.74B | 3.73B | Market Leader |